2 completed, 1 recruiting, 1 terminated, 1 withdrawn. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Recruiting 1, Terminated 1, Withdrawn 1 |
Follow Squamous Cell Carcinoma of the Esophagus: new trials by email Literature Review of Squamous Cell Carcinoma of the Esophagus trials Research Report on Squamous Cell Carcinoma of the Esophagus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of IDP-001 in Advanced or Metastatic Solid Tumors IDP-001 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Recruiting | InduPro, Inc. | 132 | 2026-07-08 | 2026-09-03 |
| A Study of KF-0210 in Advanced Solid Tumors Patients KF-0210 tablets, 120 mg, KF-0210 tablets, 240 mg, KF-0210 tablets, 450 mg - Advanced Solid Tumor, Colorectal Cancer | Phase 1 | Completed | Keythera Pharmaceuticals (Australia) Pty Ltd | 14 | 2021-03-09 | 2024-09-24 |
| Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA Monalizumab, Oxaliplatin, 5-Fluorouracil - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Withdrawn | Jules Bordet Institute | 2017-07-20 | 2017-12-19 | |
| Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction erlotinib hydrochloride, oxaliplatin, fluorouracil - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 | Completed | Wake Forest University Health Sciences | 9 | 2007-04-01 | 2018-07-02 |
| A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer oblimersen sodium, cisplatin, fluorouracil - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 15 | 2003-06-01 | 2021-02-17 |
Esophageal Squamous Cell Carcinoma (5) · Adenocarcinoma Of Esophagus (3) · Stomach Neoplasms (3) · Esophageal Neoplasms (2) · Anus Neoplasms (1) · Carcinoma, Squamous Cell (1) · Colorectal Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Squamous Cell Carcinoma of Head and Neck (1) · Urinary Bladder Neoplasms (1)
Carcinoma (5) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Esophageal Diseases (5) · Gastrointestinal Diseases (5) · Gastrointestinal Neoplasms (5) · Head and Neck Neoplasms (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Glandular and Epithelial (5) · Neoplasms, Squamous Cell (5) · Carcinoma, Squamous Cell (4) · Esophageal Neoplasms (3) · Stomach Diseases (3)
Fluorouracil (3) · Oxaliplatin (2) · Surgical Procedures, Operative (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · Cisplatin (1) · Congresses as Topic (1) · Erlotinib Hydrochloride (1) · Fluorodeoxyglucose F18 (1) · Gene Expression Profiling (1) · Immunohistochemistry (1) · Magnetic Resonance Spectroscopy (1) · Metabolic Networks and Pathways (1) · Radiation (1) · Radiotherapy (1) · atezolizumab (1)
InduPro, Inc. (1) · Jules Bordet Institute (1) · Keythera Pharmaceuticals (Australia) Pty Ltd (1) · National Cancer Institute (NCI) (1) · Wake Forest University Health Sciences (1)
United States (3) · Australia (1) · Belgium (1)
Amelie Deleporte, Physician (1) · Andreas Kaubisch (1) · Arthur Blackstock (1) · Rasha Cosman, MD (1)
2016 (1), N01CM62204 (1)